Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by scarlet1967on Jan 13, 2021 1:06pm
170 Views
Post# 32285765

RE:The dreadful deal

RE:The dreadful deal"He said as promising as the company looks he would probably avoid it"
I am trying to move on but this deal doesn't make sense at all, we have been waiting for almost two years for the NASH, even they have to do some adjustments as per PR it looks like it's definitely a phase 3.
This is the problem they created by rushing to an awful deal again primary effect is millions of these shares goes to folks who might want to bail out for a small premium putting a cap on the SP for good while(I hope I am wrong) unless we get really good news on the cancer front so those new shareholders stay put.
The secondary effect is what your friend said, when company jump on a deal like this diluting to this magnitude so early many folks start doubting the company's prospects which is understandable when company itself seems to have doubts otherwise they would wait a bit longer.
Another thing as your friend mentioned why not reaching out to decent US based brokers rather getting involved with same old crooked brokers?
None of this makes sense for a soon to be phase 3 NASH company, phase 1 oncology and growing sales.
Did they try to look for a partner?
Did they try to maximize the SP appreciation on the back a brilliant PR?
Did they reach out to US based brokers explaining the great prospects of THTX?

 
<< Previous
Bullboard Posts
Next >>